Key result
The presence of GJA1 variants increased the risk of ventricular fibrillation in STEMI patients from 49.1% to 70.8% (OR 0.40; 95% CI 0.16-0.97; P=0.04).
Why the study?
Reduced Cx43 expression increases VF risk in acute MI, and genetic background may predispose STEMI patients to primary VF.
Does the presence of GJA1 variants increase the risk of primary ventricular fibrillation in patients with acute ST-elevation myocardial infarction?
Cohort (n=966)
Does the presence of GJA1 variants increase the risk of primary ventricular fibrillation in patients with acute ST-elevation myocardial infarction?
Odds Ratio: 0.4 (95% CI 0.16–0.97)
Absolute Event Rate: 70.8% vs 49.1%
p-value: p=0.04
GJA1 (Connexin 43) variants are associated with an increased susceptibility to primary ventricular fibrillation during the acute phase of STEMI, suggesting a genetic predisposition and a potential therapeutic target.
Does not support GJA1 testing in STEMI; leaves open validation of VF risk prediction.
AIMS: Ventricular fibrillation (VF) occurring in the acute phase of ST-elevation myocardial infarction (STEMI) is the leading cause of sudden cardiac death worldwide. Several studies showed that reduced connexin 43 (Cx43) expression and reduced conduction velocity increase the risk of VF in acute myocardial infarction (MI). Furthermore, genetic background might predispose individuals to primary VF (PVF). The primary objective was to evaluate the presence of GJA1 variants in STEMI patients. The secondary objective was to evaluate the arrhythmogenic impact of GJA1 variants in STEMI patients with VF. METHODS AND RESULTS: The MAP-IDM prospective cohort study included 966 STEMI patients and was designed to identify genetic predisposition to VF. A total of 483 (50.0%) STEMI patients with PVF were included. The presence of GJA1 variants increased the risk of VF in STEMI patients [from 49.1 to 70.8%, P = 0.0423; odds ratio (OR): 0.40; 95% confidence interval: 0.16-0.97; P = 0.04]. The risk of PVF decreased with beta-blocker intake (from 53.5 to 44.8%, P = 0.0085), atrial fibrillation (from 50.7 to 26.4%, P = 0.0022), and with left ventricular ejection fraction >50% (from 60.2 to 41.4%, P < 0.0001). Among 16 GJA1 variants, three novel heterozygous missense variants were identified in three patients: V236I, H248R, and I327M. In vitro studies of these variants showed altered Cx43 localization and decreased cellular communication, mainly during acidosis. CONCLUSION: Connexin 43 variants are associated with increased VF susceptibility in STEMI patients. Restoring Cx43 function may be a potential therapeutic target to prevent PVF in patients with acute MI. CLINICAL TRIAL REGISTRATION: Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT00859300.
No takes yet. Share an insight, caveat, or question.
Chevalier et al. (2022) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=966). GJA1 variants vs. Absence of GJA1 variants was evaluated on Ventricular fibrillation (OR 0.40, 95% CI 0.16-0.97, p=0.04). The presence of GJA1 variants increased the risk of ventricular fibrillation in STEMI patients from 49.1% to 70.8% (OR 0.40; 95% CI 0.16-0.97; P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: